ArticleTransplantation2008
Bioluminescence imaging visualizes activation of nuclear factor-kappaB in mouse cardiac transplantation.
Article in Transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Gene expression profiling in PBMCs for acute rejection in lung transplant recipients reveals myeloid responses.Frontiers in transplantation · 2024Article
- Gastric Bypass Regulates Early Inflammatory Responses in High-Fat Diet-Induced Obese Mice.The Journal of surgical research · 2022Article
- Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts.Frontiers in immunology · 2020Article
- Transgenic Animal Models to Visualize Cancer-Related Cellular Processes by Bioluminescence Imaging.Frontiers in pharmacology · 2019Review
- Molecular Imaging of Acute Cardiac Transplant Rejection: Animal Experiments and Prospects.Transplantation · 2017Review
- New researches and application progress of commonly used optical molecular imaging technology.BioMed research international · 2014Review
- Role of T cell-nuclear factor κB in transplantation.Transplantation reviews (Orlando, Fla.) · 2012Review
- In vivo bioluminescence for tracking cell fate and function.American journal of physiology. Heart and circulatory physiology · 2011Review
- Molecular imaging of in vivo gene expression.Future medicinal chemistry · 2010Review
- CpG oligodeoxynucleotide triggers the liver inflammatory reaction and abrogates spontaneous tolerance.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2009Article
- Advances in bioluminescence imaging of live animal models.Current opinion in biotechnology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe purpose of the current study was to evaluate the role of bioluminescence imaging (BLI) in the determination of nuclear factor (NF)-kappaB activation in cardiac allograft rejection and ischemia-reperfusion injury.
methodsTo visualize NF-kappaB activation, luciferase transgenic mice under the control of a mouse NF-kappaB promoter (NF-kappaB-Luc) were used as donors or recipients of cardiac grafts. Alternatively, NF-kappaB-Luc spleen cells were adoptively transferred into Rag2 -/- mice with or without cardiac allografts. BLI was performed posttransplantation to detect luciferase activity that represents NF-kappaB activation.
resultsThe results show that luciferase activity was significantly increased in the cardiac allografts when NF-kappaB-Luc mice were used as recipients as well as donors. Luciferase activity was also elevated in the wild-type cardiac allografts in Rag2 -/- mice that were transferred with NF-kappaB-Luc spleen cells. CD154 monoclonal antibody (mAb) therapy inhibited luciferase activity and induced long-term survival of cardiac allografts. toll-like receptor-9 ligand, CpG DNA, enhanced luciferase activity and abrogated tolerance induction by CD154 mAb. Luciferase activity was also increased in ischemia-reperfusion injury of the cardiac grafts.
conclusionBLI using Luc-NF-kappaB mice is a noninvasive approach to visualize the activation of NF-kappaB signaling in mouse cardiac allograft rejection and ischemia-reperfusion injury. CD154 mAb can inhibit NF-kappaB activation, which is reversed by toll-like receptor engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.